RC48-ADC for her2-positive bladder cancer after bcg failure
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests an experimental drug called RC48-ADC for people with a type of early-stage bladder cancer that has not responded to the standard BCG treatment. The drug targets a protein called HER2 on cancer cells, which may help stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a high-risk, non-muscle-invasive bladder cancer that has returned after BCG therapy.
- Your tumor tests positive for HER2 (2+ or 3+ level).
- You have chosen not to have or are not eligible for bladder removal surgery.
- You are generally in good health (able to do most daily activities).
- You are not pregnant and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
This trial tests a targeted drug (RC48) combined with radiation therapy for a specific type of bladder cancer that has not invaded the muscle layer. It may be an option if your cancer has a high amount of HER2 protein and you cannot have standard BCG treatment.
This Phase 2 study tests RC48, an antibody-based drug, combined with gemcitabine to treat high-risk, non-muscle invasive bladder cancer that has not responded well to BCG or cannot receive BCG. It may help shrink tumors and reduce the chance of the cancer coming back.
This trial tests a combination of an antibody-drug conjugate (RC48) plus chemotherapy (gemcitabine) given before bladder removal surgery. It is for people with HER2-positive bladder cancer that has grown into the muscle layer.
This trial tests a new antibody-drug (RC48-ADC) together with an immunotherapy medicine (triplizumab) given before bladder surgery. It’s for people with HER2-positive muscle-invasive bladder cancer who may benefit from shrinking the tumor before radical cystectomy.
This trial tests a combination of two drugs—an antibody-drug conjugate (Disitamab Vedotin) and an immunotherapy (Toripalimab)—given for different lengths of time to treat muscle-invasive bladder cancer. The goal is to preserve the bladder while controlling the cancer.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.